The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Ridker
Paul M
PM
Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Friedewald
Vincent E
VE
Davidson
Michael H
MH
Willerson
James T
JT
Roberts
William C
WC
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D002097:C-Reactive Protein / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000517:prevention & control; D008078:Cholesterol, LDL / Q000097:blood; D005464:Fluorobenzenes / Q000627:therapeutic use; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007249:Inflammation; D015337:Multicenter Studies as Topic; D018579:Patient Selection; D011322:Primary Prevention; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome
D002097:C-Reactive Protein; D008078:Cholesterol, LDL; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides